4DMT is a clinical stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases. 4DMT seeks to unlock the full potential of genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution, which combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our product candidates. The Company is initially focused on five clinical-stage product candidates in three therapeutic areas for both rare and large market diseases: pulmonology, ophthalmology, and cardiology. 4DMT’s pulmonology pipeline utilizes the primate evolved A101 vector for low-dose intravitreal delivery, with the goal of transgene delivery in all layers and all regions of the lung with a single dose. 4DMT’s pulmonology pipeline includes 4D-710 for adults with cystic fibrosis who are ineligible for CFTR modulator therapy ow who have discontinued therapy due to adverse effects and 4D-725, which is currently in preclinical development for the treatment of patients with alpha-1 antitrypsin lung disease.